F-star Therapeutics, Inc.
FSTXNASDAQHealthcare
$7.12
+$0.00(+0.00%)
Market Cap$156511128
P/E Ratio—
52W High$7.12
52W Low$2.07
F-star Therapeutics, Inc. (FSTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FSTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2021-12 | 2020-12 | 2019-12 | 2018-12 | 2017-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $21.17M | $11.26M | $28.32M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $21.17M | $11.26M | $28.32M | $0.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $28.75M | $14.13M | $31.39M | $19.75M | $13.07M |
| G&A Expenses | $23.13M | $19.51M | $15.28M | $8.72M | $8.18M |
| Total Operating Expenses | $51.88M | $33.64M | $46.67M | $28.47M | $21.25M |
| Operating Income | ($30.71M) | ($22.39M) | ($22.50M) | ($28.47M) | ($21.25M) |
| Operating Margin %(computed) | -145.10% | -198.87% | -79.44% | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $1.00M | $0.37M |
| Interest Expense | $0.84M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($31.66M) | ($25.62M) | ($23.75M) | ($22.85M) | ($27.68M) |
| Income Tax Expense | ($0.37M) | ($0.00M) | ($0.74M) | $0.00M | $0.00M |
| Net Income | ($31.28M) | ($25.62M) | ($23.01M) | ($22.85M) | ($27.68M) |
| Net Margin %(computed) | -147.79% | -227.60% | -81.26% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.88 | $-2.82 | $-2.54 | $-1.60 | $-2.50 |
| Wtd Avg Shares | 16.65M | 9.09M | 9.07M | 14.62M | 11.15M |
| EBITDA | ($29.42M) | ($21.24M) | ($13.35M) | ($28.47M) | ($21.25M) |
| EBITDA Margin %(computed) | -138.99% | -188.71% | -47.13% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more F-star Therapeutics, Inc. data
About F-star Therapeutics, Inc. (FSTX) Income Statement
F-star Therapeutics, Inc. (FSTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2021, FSTX reported revenue of $0.02B, gross profit of $0.02B (gross margin 100.00%), and net income of ($0.03B) — a net profit margin of -147.79%.
Frequently asked questions
FSTX · 4 questionsF-star Therapeutics, Inc. (FSTX) reported revenue of $0.02B for 2021, up 88.1% year-over-year.
FSTX revenueFSTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09